Clinical evaluation of urapidil (Ebrantil®), an α1-adrenergic blocker, on micturition disturbance due to benign prostatic hyperplasia (BPH), with estimate criteria for efficacy of treatment in BPH

Akito Yamaguchi, Souichiro Akasaka, Hideyasu Iwamoto, Kazuya Omoto, Takatoshi Konishi, Kyoko Soejima, Mineo Takei, Yasuhiro Tada, Katsunori Tatsugami, Shigeru Michinaga

Research output: Contribution to journalArticle

Abstract

The subjects comprised 50 patients with benign prostatic hyperplasia (BPH) which could be treated with conservative therapy. They were given urapidil (Ebrantil®) in doses ranging from 30 mg/day to 60 mg/day for 4 weeks. The physicians in charge evaluated the effects of this drug therapy and 'estimate criteria for efficacy of treatment in BPH' was used to make an objective evaluation of the drug effects. The rates of improvement in subjective symptoms were 78.0% (39/50) according to the results of evaluation by the treating physicians and 64.3% (27/42) according to the results of evaluation by the criteria. Four irritative symptoms and three obstructive symptoms were selected from I-PSS in order to compare the transition of these symptoms. The results of this comparative study demonstrated that these two groups of symptoms were improved to similar levels. QOL scores were recorded before and after urapidil administration. Compared with the pre-treatment scores, the post-treatment scores recorded two and four weeks later showed a significant decrease. The rate of improvement calculated according to the results of QOL scoring was 67.5% (27/40). The rates of improvement in objective symptoms were 72.0% (36/50) according to the results of evaluation by the treating physicians and 46.5% (20/43) according to the results of evaluation by the criteria. The effective rates by severity were 76.0% (38/50) according to the results of global improvement rating by the treating physicians and 63.2% (24/38) according to the results of global utility rating by the criteria. No significant differences were recognized between these results. Although four patients complained of adverse effects such as vertigo, light-headedness and fatigue, no abnormal fluctuations in laboratory results were recognized. The measurement results of blood pressure and heart rate showed no significant changes. 'Estimate criteria for efficacy of treatment in BPH' has never been used to evaluate α1-adrenergic blockers. Further widespread use of the criteria is expected and this will allow doctors to select the optimum therapy for each patient by evaluating various drugs and therapeutic techniques using the criteria.

Original languageEnglish
Pages (from-to)569-575
Number of pages7
JournalNishinihon Journal of Urology
Volume61
Issue number7
Publication statusPublished - Jul 1 1999
Externally publishedYes

Fingerprint

Adrenergic Antagonists
Urination
Prostatic Hyperplasia
Physicians
Drug Evaluation
Vertigo
Dizziness
Therapeutics
Fatigue
Heart Rate
Blood Pressure
Drug Therapy
urapidil
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Clinical evaluation of urapidil (Ebrantil®), an α1-adrenergic blocker, on micturition disturbance due to benign prostatic hyperplasia (BPH), with estimate criteria for efficacy of treatment in BPH. / Yamaguchi, Akito; Akasaka, Souichiro; Iwamoto, Hideyasu; Omoto, Kazuya; Konishi, Takatoshi; Soejima, Kyoko; Takei, Mineo; Tada, Yasuhiro; Tatsugami, Katsunori; Michinaga, Shigeru.

In: Nishinihon Journal of Urology, Vol. 61, No. 7, 01.07.1999, p. 569-575.

Research output: Contribution to journalArticle

Yamaguchi, Akito ; Akasaka, Souichiro ; Iwamoto, Hideyasu ; Omoto, Kazuya ; Konishi, Takatoshi ; Soejima, Kyoko ; Takei, Mineo ; Tada, Yasuhiro ; Tatsugami, Katsunori ; Michinaga, Shigeru. / Clinical evaluation of urapidil (Ebrantil®), an α1-adrenergic blocker, on micturition disturbance due to benign prostatic hyperplasia (BPH), with estimate criteria for efficacy of treatment in BPH. In: Nishinihon Journal of Urology. 1999 ; Vol. 61, No. 7. pp. 569-575.
@article{8019dcd55d7342c881a63548637419f3,
title = "Clinical evaluation of urapidil (Ebrantil{\circledR}), an α1-adrenergic blocker, on micturition disturbance due to benign prostatic hyperplasia (BPH), with estimate criteria for efficacy of treatment in BPH",
abstract = "The subjects comprised 50 patients with benign prostatic hyperplasia (BPH) which could be treated with conservative therapy. They were given urapidil (Ebrantil{\circledR}) in doses ranging from 30 mg/day to 60 mg/day for 4 weeks. The physicians in charge evaluated the effects of this drug therapy and 'estimate criteria for efficacy of treatment in BPH' was used to make an objective evaluation of the drug effects. The rates of improvement in subjective symptoms were 78.0{\%} (39/50) according to the results of evaluation by the treating physicians and 64.3{\%} (27/42) according to the results of evaluation by the criteria. Four irritative symptoms and three obstructive symptoms were selected from I-PSS in order to compare the transition of these symptoms. The results of this comparative study demonstrated that these two groups of symptoms were improved to similar levels. QOL scores were recorded before and after urapidil administration. Compared with the pre-treatment scores, the post-treatment scores recorded two and four weeks later showed a significant decrease. The rate of improvement calculated according to the results of QOL scoring was 67.5{\%} (27/40). The rates of improvement in objective symptoms were 72.0{\%} (36/50) according to the results of evaluation by the treating physicians and 46.5{\%} (20/43) according to the results of evaluation by the criteria. The effective rates by severity were 76.0{\%} (38/50) according to the results of global improvement rating by the treating physicians and 63.2{\%} (24/38) according to the results of global utility rating by the criteria. No significant differences were recognized between these results. Although four patients complained of adverse effects such as vertigo, light-headedness and fatigue, no abnormal fluctuations in laboratory results were recognized. The measurement results of blood pressure and heart rate showed no significant changes. 'Estimate criteria for efficacy of treatment in BPH' has never been used to evaluate α1-adrenergic blockers. Further widespread use of the criteria is expected and this will allow doctors to select the optimum therapy for each patient by evaluating various drugs and therapeutic techniques using the criteria.",
author = "Akito Yamaguchi and Souichiro Akasaka and Hideyasu Iwamoto and Kazuya Omoto and Takatoshi Konishi and Kyoko Soejima and Mineo Takei and Yasuhiro Tada and Katsunori Tatsugami and Shigeru Michinaga",
year = "1999",
month = "7",
day = "1",
language = "English",
volume = "61",
pages = "569--575",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "7",

}

TY - JOUR

T1 - Clinical evaluation of urapidil (Ebrantil®), an α1-adrenergic blocker, on micturition disturbance due to benign prostatic hyperplasia (BPH), with estimate criteria for efficacy of treatment in BPH

AU - Yamaguchi, Akito

AU - Akasaka, Souichiro

AU - Iwamoto, Hideyasu

AU - Omoto, Kazuya

AU - Konishi, Takatoshi

AU - Soejima, Kyoko

AU - Takei, Mineo

AU - Tada, Yasuhiro

AU - Tatsugami, Katsunori

AU - Michinaga, Shigeru

PY - 1999/7/1

Y1 - 1999/7/1

N2 - The subjects comprised 50 patients with benign prostatic hyperplasia (BPH) which could be treated with conservative therapy. They were given urapidil (Ebrantil®) in doses ranging from 30 mg/day to 60 mg/day for 4 weeks. The physicians in charge evaluated the effects of this drug therapy and 'estimate criteria for efficacy of treatment in BPH' was used to make an objective evaluation of the drug effects. The rates of improvement in subjective symptoms were 78.0% (39/50) according to the results of evaluation by the treating physicians and 64.3% (27/42) according to the results of evaluation by the criteria. Four irritative symptoms and three obstructive symptoms were selected from I-PSS in order to compare the transition of these symptoms. The results of this comparative study demonstrated that these two groups of symptoms were improved to similar levels. QOL scores were recorded before and after urapidil administration. Compared with the pre-treatment scores, the post-treatment scores recorded two and four weeks later showed a significant decrease. The rate of improvement calculated according to the results of QOL scoring was 67.5% (27/40). The rates of improvement in objective symptoms were 72.0% (36/50) according to the results of evaluation by the treating physicians and 46.5% (20/43) according to the results of evaluation by the criteria. The effective rates by severity were 76.0% (38/50) according to the results of global improvement rating by the treating physicians and 63.2% (24/38) according to the results of global utility rating by the criteria. No significant differences were recognized between these results. Although four patients complained of adverse effects such as vertigo, light-headedness and fatigue, no abnormal fluctuations in laboratory results were recognized. The measurement results of blood pressure and heart rate showed no significant changes. 'Estimate criteria for efficacy of treatment in BPH' has never been used to evaluate α1-adrenergic blockers. Further widespread use of the criteria is expected and this will allow doctors to select the optimum therapy for each patient by evaluating various drugs and therapeutic techniques using the criteria.

AB - The subjects comprised 50 patients with benign prostatic hyperplasia (BPH) which could be treated with conservative therapy. They were given urapidil (Ebrantil®) in doses ranging from 30 mg/day to 60 mg/day for 4 weeks. The physicians in charge evaluated the effects of this drug therapy and 'estimate criteria for efficacy of treatment in BPH' was used to make an objective evaluation of the drug effects. The rates of improvement in subjective symptoms were 78.0% (39/50) according to the results of evaluation by the treating physicians and 64.3% (27/42) according to the results of evaluation by the criteria. Four irritative symptoms and three obstructive symptoms were selected from I-PSS in order to compare the transition of these symptoms. The results of this comparative study demonstrated that these two groups of symptoms were improved to similar levels. QOL scores were recorded before and after urapidil administration. Compared with the pre-treatment scores, the post-treatment scores recorded two and four weeks later showed a significant decrease. The rate of improvement calculated according to the results of QOL scoring was 67.5% (27/40). The rates of improvement in objective symptoms were 72.0% (36/50) according to the results of evaluation by the treating physicians and 46.5% (20/43) according to the results of evaluation by the criteria. The effective rates by severity were 76.0% (38/50) according to the results of global improvement rating by the treating physicians and 63.2% (24/38) according to the results of global utility rating by the criteria. No significant differences were recognized between these results. Although four patients complained of adverse effects such as vertigo, light-headedness and fatigue, no abnormal fluctuations in laboratory results were recognized. The measurement results of blood pressure and heart rate showed no significant changes. 'Estimate criteria for efficacy of treatment in BPH' has never been used to evaluate α1-adrenergic blockers. Further widespread use of the criteria is expected and this will allow doctors to select the optimum therapy for each patient by evaluating various drugs and therapeutic techniques using the criteria.

UR - http://www.scopus.com/inward/record.url?scp=6544281466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6544281466&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:6544281466

VL - 61

SP - 569

EP - 575

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 7

ER -